Biomeditsina va amaliyot jurnali, 2022 №1
Subject of the article
THE IMPORTANCE OF NEUROTROPHICAL FACTORS IN THE PATHOGENESIS OF PRIMARY HEADACHES (105-110)
Authors
KHALIMOVA Khanifa Mukhsinovna RASHIDOVA Nilufar Safoyevna HOLMURATOVA Bahtigul Nurmuhammat kizi RAKHMATULLAEVA Gulnora Kutbitdinovna
Institution
Tashkent medical academy
Abstract
Cephalgia is a painful process that interferes with the normal functioning of the body, with a global prevalence of headache among the adult population (clinical symptoms observed at least 1 time in the last year) is approximately 50%. It is known that all existing headaches are studied in two major groups: primary H and secondary H. Despite the prevalence of primary headaches, particularly migraine and tension headaches, and their significant socioeconomic disadvantages, their pathophysiology has not been fully studied. For many years, the onset of migraine symptoms has been thought to be associated with changes in vascular tone, followed by a number of scientific studies showing that the mechanism of the pain phase in migraine is related to trigeminovascular (TVT) system activation and pain neuropeptides. In modern neurology, the role of neutrophilic factors in the development of pain is being studied. In this paper, we consider the role of cerebral neurotrophic factor (BDNF) in the pathogenesis of primary cephalgias.
Key words
headache, migraine, tension headache, pathogenesis, neurotrophic factor, hormone, BDNF, pain.
Literature
1. Первичные головные боли: диагностика и лечение. Методические рекомендации.– В.В. Осипова. – Москва – 2017. – 27 с.; 2. ВОЗ, апрель, 2016г., https://www.who.int/ru/news-room/fact-sheets/detail/headachedisorders; 3. Гафуров Б.Г. Мигрень: Методич. реком. – 2009. - С. 6.; 4. Г.Р.Табеева “Головная боль” руководство для врачей, 2е изд.,пере-раб.доп.- ГЭОТАР медиа, 2018г., 29 стр.; 5. Ибадуллаев З.Р. Асаб касалликлари. – Тошкент, 2014. - С. 863.; 6. Вейн А.М. Головная боль: классификация, клиника, диагностика, лечение / А.М. Вейн, О.А. Колосова, Н.А. Яковлев и др. — М., 1994. — 286 с; 7. Мищенко Т.С. Современные подходы к фармакотерапии мигрени / Т.С. Мищенко, В.Н. Мищенко // Междунар. неврол. журнал. — 2015. — № 1 (71). — С. 90-98.; 8. Осипова В.В. Первичные головные боли: диагностика, клиника, терапия. Практическое руководство / В.В. Осипова, Г.Р. Табеева. — М.: Медицинское информационное агентство, 2014. — 336 с; 9. Сергеев А.В. Центральная нейрональная гипервозбудимость — предиспозиция к мигрени / А.В. Сергеев, Г.Р. Табеева, Ю.Э. Азимова // Рос. журн. боли. — 2010. — № 2. — С. 3-8.; 10. Снопкова Е.В. Анализ клинико-психологических и нейрофизиологических особенностей мигрени у пациентов старшей возрастной группы / Е.В. Снопкова, А.В. Сергеев, В.В. Осипова // Рос. журн. боли. — 2012. — № 1. — С. 44.; 11. Goadsby P.J. Pathophysiology of Migraine: A disease of the Brain // Headache / Goadsby P.J., Silberstein S.D. (eds). — Butterworth-Heinemann, 1997. — P. 5-25.; 12. Wei E.P. Calcitonin gene-related peptide mediates nitroglicerine and sodium nitroprusside vasodilatation in feline cerebral arterioles / E.P. Wei, M.A. Moskowitz, P. Boccalini et al. // Circ. Res. — 1992. — 70. — 1313. ]; 13. 13. Neurotrophins and Migraine, L.B. Martins, A.L. Teixeira, R.B. Domingues, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, 2017, Elsevier, Vitamins and Hormones, Volume 104; 14. Leone M, Bussone G (2009) Pathophysiology of trigeminalautonomic cephalalgias. Lancet Neurol 8(8):755–764; 15. Lipsky RH, Marini AM (2007) Brain-derived neurotrophic factorin neuronal survival and behavior-related plasticity. Ann N Y Acad Sci 1122:130–143; 16. R.C. Malenka, M.F. Bear, LTP and LTD: an embarrassment of riches, Neuron, 44 (2004), pp. 5-21; 17. Thompson SW, Bennett DL, Kerr BJ, Bradbury EJ, McMahonSB (1999) Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Proc Natl Acad Sci USA 96(14):7714–7718; 18. Buldyrev I, Tanner NM, Hsieh HY, Dodd EG, Nguyen LT,Balkowiec A (2006) Calcitonin gene-related peptide enhances release of native brain-derived neurotrophic factor from trigeminal ganglion neurons. J Neurochem 99(5):1338–1350]; 19. Balkowiec-Iskra E, Vermehren-Schmaedick A, Balkowiec A(2011) Tumor necrosis factoralpha increases brain-derived neurotrophic factor expression in trigeminal ganglion neurons in an activity-dependent manner. Neuroscience 180:322–333; 20. A.L. Allen, K.E. McCarson Estrogen increases nociception-evoked brain-derived neurotrophic factor gene expression in the female rat Neuroendocrinology, 81 (2005), pp. 193 199; 21. Luciana CadoreStefaniacIraci Lucena da SilvaTorresabcIzabel Cristina Custodiode SouzaacJoanna RipollRoziskyacFelipeFregnidefWolneiCaumoabc, BDNF как модификатор эффекта для гендерных эффектов на пороги боли в здоровых предметах, Neuroscience Letters, Volume 514, Issue 1, 11 April 2012, Pages 62-66; 22. S.D. Kuipers, C.R. Bramham, Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy, Curr. Opin. Drug Discov. Devel., 9 (2006), pp. 580-586; 23. K. Martinowich, H. Manji, B. Lu, New insights into BDNF function in depression and anxiety, Nat. Neurosci., 10 (2007), pp. 1089-1093.